Response to combined molecular targeting: defining the role of P-STAT3.
Level V
Where this comes from
- Record sourced from PubMed, PMID 21266530.
- Also identified by DOI 10.1158/1078-0432.CCR-10-2925 and PMC identifier 3149866.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Src family kinase (SFK)-targeting agents are currently undergoing clinical investigation for treatment of solid malignancies. Epidermal growth factor receptor (EGFR)-independent phosphorylation of STAT3 (P-STAT3) has been identified as a mechanism of tumor resistance to agents targeting SFK. Tumor P-STAT3 levels may be an important indicator of EGFR- and SKF-targeted antitumor treatment efficacy.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- ErbB Receptors
- Pancreatic Neoplasms
- Protein Kinase Inhibitors
- STAT3 Transcription Factor